A new antibody developed preclinically showed that it could potentially cure metabolic diseases, including Type 2 diabetes and fatty liver disease. The new antibody worked by targeting the hormone aP2, which is also known as FABP4, in fat-storing tissues.
A new antibody developed preclinically showed that it could potentially cure metabolic diseases, including Type 2 diabetes and fatty liver disease. The new antibody worked by targeting the hormone aP2, which is also known as FABP4, in fat-storing tissues.
Share this Article
Recommended